Interactions on record — worth a quick check against your medications. Based on 6 of 8 ingredients. Check your meds →
Dietary supplement

Jarro-Dophilus EPS 25 Billion CFU Ingredients & Drug Interactions

by Jarrow Formulas

Jarro-Dophilus EPS 25 Billion CFU label
See full label image
Capsule Category: Non-nutrient/non-botanical
Most serious interaction: Moderate
Clinical methodology reviewed by · Updated Sep 23, 2026 · Label data from the NIH DSLD
What is this page for?

First and foremost: checking Jarro-Dophilus EPS 25 Billion CFU against your medications. The heart of this page is the interaction checker and the full interaction report — how this product’s ingredients may interact with prescription and over-the-counter medicines you may be taking.

Around that, we add a pharmacist’s high-level view of the product as a whole — what’s inside, the evidence for its stated use, how transparent the label is, and what safety data exists — so you can see the full picture in one place. It’s educational information from our licensed clinical databases and the clinical staff at HelloPharmacist — not medical advice — and we don’t sell or endorse products. Our editorial policy

The interaction bottom line Most serious interaction: Moderate

Jarro-Dophilus EPS 25 Billion CFU is a dietary supplement by Jarrow Formulas with 8 active ingredients. Its ingredients are commonly taken for digestive health and regularity, infant colic and gut support, diarrhea (including antibiotic-related).Based on those ingredients, 182 medications have a known interaction with it, the most serious rated moderate. The ingredients most likely to interact are Bifidobacterium breve R0070, Lacticaseibacillus rhamnosus R0011, Lactiplantibacillus plantarum R1012. Use the checker below to test your specific medication, or read the full HelloPharmacist Interaction Report.

Jump to a section

Check Your Meds Against Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas

Ask about any prescription or over-the-counter medication and we check it for interactions with Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas — and tell you which ingredient is responsible.

Pharmacist-reviewed data Checks every ingredient Answer in seconds
Prefer a human? Send your question to our licensed pharmacists — free, answered by email within 24 hours.

HelloPharmacist Scorecard of Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas

Our pharmacy team’s full take, with four database checks built into the cards below — a summary of what is known, not a grade of the product itself.

From our pharmacy team — supplement deep dive

Generated from HelloPharmacist’s pharmacist-curated databases and editorial rules · Last generated Aug 13, 2026

What’s inside

Low disclosure
Ingredient Transparency · database check
Low

Most active ingredients don't disclose an individual amount — you can't tell how much of each you're getting.

Why this rating?
  • The label discloses an exact amount for 0 of its 8 active ingredients.
  • “Proprietary Probiotic Blend” is a proprietary blend — the label gives one combined amount (413 mg) without saying how much of each component you get.

Jarro-Dophilus EPS 25 Billion CFU is built around 8 active ingredients: a proprietary blend of six named probiotic bacterial strains plus two others. The six named strains are Bifidobacterium breve, Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, Lacticaseibacillus casei, Bifidobacterium longum, and Lactobacillus helveticus—each chosen for their ability to colonize the gut and support digestive and immune function.

The product also contains standard inactive ingredients (potato starch, cellulose derivatives, alginate, and others) that serve as fillers and capsule material.

Does it work?

Moderate evidence
Evidence for Intended Use · database check
By FDA rules, dietary supplements can’t claim to treat, cure, or prevent disease — so labels speak in careful marketing language. We discern each product’s intended use from its name, label claims, and label statements, then grade the clinical evidence for that use. How these ratings are computed
Moderate

Some clinical evidence supports this product's ingredients for its stated purpose, but it isn't conclusive.

Why this rating?
  • The label markets this product for: Digestive health and probiotic support.
  • We looked for evidence on: Antibiotic-associated diarrhea, Colic, Constipation, Diarrhea, Gut microbiome balance, Digestive regularity — and 1 related terms.
  • The strongest evidence on file: Lacticaseibacillus Rhamnosus is rated "Possibly Effective" for Antibiotic-associated diarrhea (Natural Medicines).
  • Also on file: Lactiplantibacillus Plantarum is rated "Possibly Ineffective" for Antibiotic-associated diarrhea.
  • Also on file: Bifidobacterium Breve is rated "Insufficient Reliable Evidence To Rate" for Antibiotic-associated diarrhea, Constipation, Rotaviral diarrhea, Colic, and more.

The evidence for these strains is mixed and condition-specific. Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, and Bifidobacterium breve each show some promise for specific uses—for example, L. rhamnosus and L. plantarum are rated Possibly Effective for atopic dermatitis (eczema), and L. rhamnosus is also Possibly Effective for antibiotic-associated diarrhea.

L. plantarum additionally shows Possibly Effective ratings for high cholesterol, ulcerative colitis, and common cold. For many other claims (cognitive decline, allergies, anxiety), the evidence we hold is Insufficient to rate these strains reliably.

Because you're getting a blend, your actual benefit will depend on which strain is most active for your specific health goal.

The evidence, ingredient by ingredient Bifidobacterium Breve Lacticaseibacillus Rhamnosus Lactiplantibacillus Plantarum Lacticaseibacillus Casei Bifidobacterium Longum Lactobacillus Helveticus

How safe is it?

Well-documented data
Safety Information · database check
Well characterized

Adverse-effect, pregnancy, and general safety data are on file for most of these ingredients.

Why this rating?
  • We hold adverse-effect (side-effect) data for 6 of the 6 matched ingredients.
  • Pregnancy & breastfeeding safety ratings cover 6 of 6.
  • General safety write-ups exist for 6 of 6.
  • Remember: this measures how much safety information exists. Thin data is not the same as being safe.

All six checked strains are generally well tolerated in healthy people. However, the facts note important caution: probiotics contain live organisms, and in rare cases—especially in very ill, critically ill, or severely immunocompromised patients—they have been associated with bacterial bloodstream infections (bacteremia) and serious infections.

Infants in neonatal intensive care and people with weakened immune systems are at higher risk. Common mild side effects reported with probiotics include bloating, flatulence, diarrhea, abdominal pain, and nausea, though these are uncommon.

For Lacticaseibacillus rhamnosus and Lacticaseibacillus casei, pregnancy is rated Possibly Safe and lactation data are limited or not on file; for Lactiplantibacillus plantarum, pregnancy is Possibly Safe and lactation data are not on file. Bifidobacterium longum is rated Possibly Safe in both pregnancy and lactation.

Data for Bifidobacterium breve and Lactobacillus helveticus in pregnancy and lactation are not on file. Because safety data are limited overall, check with your healthcare provider before use, especially if you're pregnant, nursing, or have a weakened immune system.

Side effects, ingredient by ingredient Bifidobacterium Breve Lacticaseibacillus Rhamnosus Lactiplantibacillus Plantarum Lacticaseibacillus Casei Bifidobacterium Longum Lactobacillus Helveticus

Meds to double-check

Moderate interaction found
Known Interaction Concern · database check
Moderate identified

The most serious documented interaction for these ingredients is Moderate. Check your medications for a personalized result.

Why this rating?
  • 6 of the 6 matched ingredients can interact with medications — Bifidobacterium Breve, Bifidobacterium Longum, Lacticaseibacillus Casei, Lacticaseibacillus Rhamnosus, Lactiplantibacillus Plantarum, among others.
  • The most serious interaction on file is rated Moderate.
  • For scale: 182 individual medications appear in the full list. A big number alone doesn't make a product dangerous — what matters is whether YOUR medication is on it, so run yours through the interaction checker on this page.

If you take any antibiotic drug, you must check with your doctor or pharmacist about timing before adding this product. All six checked probiotic strains carry a Moderate interaction with antibiotics that may reduce the probiotic's effectiveness.

Separating doses (often by a few hours) is typically the solution, but the details depend on your specific antibiotic and your health situation.

Check your own medication Run your meds through the checker above

The bottom line

Scorecard at a glanceFormula with limited ingredient disclosure with some supporting evidence for its stated purpose. Moderate medication interactions have been identified, and safety information is well characterized.

This product is a multi-strain probiotic aimed at people looking to support gut health and digestion. It's generally well tolerated in healthy individuals, though the evidence for specific benefits is incomplete depending on your goal.

The key caution is if you're taking antibiotics: talk with your doctor or pharmacist about timing, since antibiotics can reduce the effectiveness of these live organisms. If you're seriously ill, immunocompromised, pregnant, or nursing, discuss this with your healthcare provider before starting.

Educational only — not medical advice; always confirm with your pharmacist. Our editorial policy · How we use AI

Assessment coverage: 6 of 8 active ingredients matched to our full ingredient reviews (monographs). Based on the product label dated Feb 22, 2024.

This Scorecard evaluates available label information, ingredient evidence, and known medication-safety considerations. It does not independently verify product identity, purity, potency, contamination, or manufacturing quality. How these ratings are computed

At a glance

General information

Key facts about Jarro-Dophilus EPS 25 Billion CFU, straight from the product label.

Brand Jarrow Formulas
Barcode (UPC) 790011030409
Net contents 30 Veggie Capsule(s)
Market status On market
Date entered into DSLD Feb 22, 2024
DSLD ID 307632
Product type Non-nutrient/non-botanical
Supplement form Capsule
Dietary claims / uses All Other, Structure/Function
Intended target group(s) Vegetarian, Adult (18 - 50 Years), Gluten Free
From the label
Everything in this section is reproduced from the manufacturer’s own product label — it’s the label speaking, not HelloPharmacist. We show it so you can see exactly what the maker states; we don’t verify or endorse those statements.

Supplement Facts

The label details for Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas, sourced from the NIH Dietary Supplement Label Database.

Supplement Facts

Daily Value (DV) Target Group(s):
Adults and children 4 or more years of age
Minimum serving Sizes:
1 Capsule(s)
Maximum serving Sizes:
1 Capsule(s)
Servings per container
30
UPC/BARCODE
790011030409
IngredientAmount% DV
Proprietary Probiotic Blend413 mg--
Bifidobacterium breve R00700 NP--
Lacticaseibacillus rhamnosus R00110 NP--
Lactiplantibacillus plantarum R10120 NP--
Lacticaseibacillus casei R02150 NP--
Bifidobacterium longum BB5360 NP--
Pediococcus acidilactici R10010 NP--
Lactobacillus helveticus R00520 NP--
Lactococcus lactis lactis R10580 NP--

Other ingredients: Potato Starch, Hydroxypropyl Methylcellulose, Water, Hypromellose, Ethylcellulose, Sodium Alginate, Medium Chain Triglyceride, Oleic Acid, Stearic Acid, Magnesium Stearate, Ascorbic Acid

Tap any ingredient to jump to its full detail below.

Label statements
These statements are the manufacturer’s wording, reproduced from the product label — the label is saying it, not HelloPharmacist. We don’t verify or endorse them.
Precautions

Contains: Milk and soy (in trace amounts).

Warning: Consult a healthcare professional before using this product if you are pregnant, nursing, under the age of 18, are taking medication or have a medical condition; if adverse reactions occur, discontinue use.

Warning: Consult a healthcare professional before using this product if you are pregnant, nursing, under the age of 18, are taking medication or have a medical condition; if adverse reactions occur, discontinue use.

Keep out of the reach of children.

Formulation

IGEN Non-GMO tested

EnteroGuard Protects probiotics from stomach acid

Blister packed Protects probiotics From moisture and oxygen for superior stability

Strains Matter When it comes to effective probiotics, clinically documented Strains Matter. As an innovator of consumer probiotics since 1986, Jarrow Formulas takes great pride in using high-quality and scientifically documented strains that have been developed through years of research and innovation.

Star Technology Lallemand Made in Canada by Lallemand Health Solutions, Inc.

Vegetarian

Enhanced probiotic system Gut restore Supports immune health and the development of a healthy gut

Gluten free

Live Probiotic Guarantee When kept under recommended storage conditions, Jarrow Probiotics are formulated to ensure CFU counts are guaranteed within best used before date.

Storage

Shelf Life: Stability Formulated with strains that are stable at room temperature (77 degrees F)

No Refrigeration Necessary Does not require refrigeration and can be stored at room temperature in a cool, dry place. Avoid storage at temperature above 77 degrees F (25 degrees C). Refrigeration, however extends shelf life.

Store in a cool, dry place.

Suggested/Recommended/Usage/Directions

Suggested Use: Adults take 1 capsule once a day with water or juice, preferably on an empty stomach, or as directed by your qualified healthcare professional.

Seals/Symbols

IPRO

IGEN Non-GMO tested

Brand IP Statement(s)

Copyright 2023 Jarrow Formulas

Formula

8 clinically studied strains 8 complementary strains Enteroguard coating

8 Clinically Studied Strains in an Enhanced Probiotic System (EPS) Jarro-Dophilus EPS supports the health of the intestinal tract with a balanced mixture of carefully selected probiotic strains for intestinal and immune health. These strains have been clinically shown to have a positive influence on intestinal and/or immune health. Our 8 complementary strains of probiotic bacteria are delivered via proprietary enteric coated capsules (EnteroGuard) that protect it from stomach acid and delivers the potency of friendly bacteria needed to support a healthy-gut. Jarro-Dophilus EPS is blister-packed to protect the capsules from moisture and room temperature stable so it does not require refrigeration.

FDA Statement of Identity

Probiotics Supplement

FDA Disclaimer Statement

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

General Statements

Probiotics

Is this label outdated? Report a formula or label change and our pharmacy team will review it.

See for yourself

Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas label

The label scan from the NIH Dietary Supplement Label Database. Tap to enlarge.

Jarro-Dophilus EPS 25 Billion CFU label

Label images are published by the NIH Dietary Supplement Label Database for the version of this product on file. Always read your actual product label.

View the full label (PDF)
What’s inside

The Ingredients in Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas

These are the 8 active ingredients this product is made of. Select any to open its full monograph.

Serving size1 Capsule(s) Dosage formCapsule Servings per container30 Amounts shown are per serving.

Most supplement products combine several ingredients, and a medication can interact with the product through any one of them. Each ingredient below shows whether it has known drug interactions.

Proprietary Probiotic Blend

413 mg per serving

Other (inactive) ingredients: Potato Starch, Hydroxypropyl Methylcellulose, Water, Hypromellose, Ethylcellulose, Sodium Alginate, Medium Chain Triglyceride, Oleic Acid, Stearic Acid, Magnesium Stearate, Ascorbic Acid. These complete the product’s ingredient list but are not active constituents.

Interaction report

Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas Drug Interactions

Want to check YOUR meds against Jarro-Dophilus EPS 25 Billion CFU?

Ask about interactions with your drugs in plain English — “Can I take it with lisinopril?” — and we find you the answer in seconds, ingredient by ingredient.

 Go to the checker
182Drugs
182 Moderate

Ingredients driving the most interactions

Bifidobacterium breve R0070 182
Lacticaseibacillus rhamnosus R0011 182
Lactiplantibacillus plantarum R1012 182
Lacticaseibacillus casei R0215 182
Bifidobacterium longum BB536 182

Individual Drug Interactions

The ingredients in Jarro-Dophilus EPS 25 Billion CFU interact with 182 drugs. Click any drug to see the details.

6 of the 8 ingredients in Jarro-Dophilus EPS 25 Billion CFU interact with drugs. Each result below shows which ingredient is responsible. Bifidobacterium breve R0070 Lacticaseibacillus rhamnosus R0011 Lactiplantibacillus plantarum R1012 Lacticaseibacillus casei R0215 Bifidobacterium longum BB536 Lactobacillus helveticus R0052

Each ingredient & the kinds of drugs it affects

For each ingredient in Jarro-Dophilus EPS 25 Billion CFU with known interactions, here are the types of medications they can affect. Open any type for the detail — or search your exact drug in the checker above.

Bifidobacterium breve R00701 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium breve with antibiotic drugs might decrease the effectiveness of B. breve.
Since B. breve preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. breve preparations by at least 2 hours.

Likelihood Probable Evidence D
Bifidobacterium breve R0070 full monograph & interactions

Lacticaseibacillus rhamnosus R00111 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lacticaseibacillus rhamnosus with antibiotic drugs might decrease the effectiveness of L. rhamnosus.
L. rhamnosus preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. rhamnosus preparations by at least two hours.

Likelihood Probable Evidence D
Lacticaseibacillus rhamnosus R0011 full monograph & interactions

Lactiplantibacillus plantarum R10121 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactiplantibacillus plantarum with antibiotic drugs might decrease the effectiveness of L. plantarum.
L. plantarum preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. plantarum preparations by at least two hours.

Likelihood Probable Evidence D
Lactiplantibacillus plantarum R1012 full monograph & interactions

Lacticaseibacillus casei R02151 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lacticaseibacillus casei with antibiotic drugs might decrease the effectiveness of L. casei.
L. casei preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. casei preparations by at least two hours.

Likelihood Probable Evidence D
Lacticaseibacillus casei R0215 full monograph & interactions

Bifidobacterium longum BB5361 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Bifidobacterium longum with antibiotic drugs might decrease the effectiveness of B. longum.
Since B. longum preparations usually contain live and active organisms, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and B. longum preparations by at least 2 hours.

Likelihood Probable Evidence D
Bifidobacterium longum BB536 full monograph & interactions

Lactobacillus helveticus R00521 drug type · 182 drugs

Antibiotic Drugs

Theoretically, taking Lactobacillus helveticus with antibiotic drugs might decrease the effectiveness of L. helveticus.
Lactobacillus helveticus preparations usually contain live and active organisms. Therefore, simultaneously taking antibiotics might kill a significant number of the organisms. Tell patients to separate administration of antibiotics and L. helveticus preparations by at least two hours.

Likelihood Probable Evidence D
Lactobacillus helveticus R0052 full monograph & interactions
The maker

Brand information

Manufacturer and brand details for Jarro-Dophilus EPS 25 Billion CFU, from the product label.

Jarrow Formulas

See all Jarrow Formulas products
Name
Jarrow Formulas, Inc.
City
Sherman Oaks
State
CA
ZipCode
91403
Phone Number
1-866-459-4154
Web Address
www.Jarrow.com
Pharmacist Counseling Corner

Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas: Common Questions

Does Jarro-Dophilus EPS 25 Billion CFU by Jarrow Formulas interact with any medications?
Yes. Based on its ingredients, Jarro-Dophilus EPS 25 Billion CFU has a known interaction with 182 medications. Use the checker to see how it interacts with a specific drug.
How can one product interact with so many drugs?
Jarro-Dophilus EPS 25 Billion CFU contains 8 active ingredients, and an interaction can come from any of them. We check every ingredient, combine the results into one list per medication, and show which ingredient and mechanism is responsible.
Where does this information come from?
The product label data comes from the NIH Dietary Supplement Label Database (DSLD); the interaction data is built on the Natural Medicines database and reviewed by HelloPharmacist pharmacists.
Can I take this probiotic while I'm on an antibiotic?
Probably yes, but you'll need to space the doses apart. Antibiotics can kill the live bacteria in this product, reducing how well it works. Talk with your doctor or pharmacist about the best timing for your specific antibiotic—usually a gap of a few hours between doses works, but it depends on the drug.
Is this safe during pregnancy or while breastfeeding?
Three of the strains (Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, and Bifidobacterium longum) are rated Possibly Safe in pregnancy; for the others or during lactation, the data aren't complete. Since safety data for probiotics in general are limited, check with your doctor or midwife for personalized advice before using.
What does this product actually do?
Each strain has different evidence. Lacticaseibacillus rhamnosus and Lactiplantibacillus plantarum show the most promise—they're Possibly Effective for eczema and antibiotic-related diarrhea, and L. plantarum may help with high cholesterol and colds. For other uses like cognitive or mood support, we don't have reliable evidence yet.
What side effects might I experience?
Mild gastrointestinal effects like bloating, gas, diarrhea, and abdominal discomfort are the most common, though they're uncommon overall. In very ill or immunocompromised patients, there's a rare risk of serious infection. If you develop fever, severe pain, or signs of infection after starting, contact your doctor right away.
Does this have any fillers?
Yes. The product contains inactive ingredients like potato starch, cellulose, and alginate that serve as fillers and capsule material. If you're sensitive to any of these, check the full ingredient list with your pharmacist.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Not sure if Jarro-Dophilus EPS 25 Billion CFU is safe with your meds?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

Label information is sourced from the NIH Dietary Supplement Label Database and reflects the product version on file; always read your actual product label. This page is for education only and is not a substitute for professional medical advice. Confirm with your pharmacist or doctor before combining supplements and medications.

Jarro-Dophilus EPS 25 Billion CFU label
Go deeper

The Full Monographs Behind Jarro-Dophilus EPS 25 Billion CFU’s Ingredients

Every ingredient we hold a full HelloPharmacist monograph for — uses, evidence, safety, and the complete interaction list.

Herb & supplement monograph

Bifidobacterium Breve

Interacts with 182 drugs

Bifidobacterium breve is a 'friendly' gut bacterium taken as a probiotic, most often to support digestion and balance the gut microbiome. Some studies suggest possible benefits for certain d...

Read the full Bifidobacterium Breve monograph → Herb & supplement monograph

Lacticaseibacillus Rhamnosus

Interacts with 182 drugs

Lacticaseibacillus rhamnosus (often labeled L. rhamnosus GG) is a well-studied probiotic bacterium used mainly for diarrhea and general gut health. It is considered safe for most healthy peo...

Read the full Lacticaseibacillus Rhamnosus monograph → Herb & supplement monograph

Lactiplantibacillus Plantarum

Interacts with 182 drugs

Lactiplantibacillus plantarum is a 'friendly' bacterium (probiotic) found in fermented foods and many supplements, studied mainly for digestive health. It is generally well tolerated in heal...

Read the full Lactiplantibacillus Plantarum monograph → Herb & supplement monograph

Lacticaseibacillus Casei

Interacts with 182 drugs

Lacticaseibacillus casei (formerly Lactobacillus casei) is a 'friendly' probiotic bacterium found in fermented foods and many supplements. It is most studied for digestive issues like diarrh...

Read the full Lacticaseibacillus Casei monograph → Herb & supplement monograph

Bifidobacterium Longum

Interacts with 182 drugs

Bifidobacterium longum is a 'friendly' bacterium found naturally in the human gut and used as a probiotic. It is generally well tolerated and is most studied for digestive issues, though evi...

Read the full Bifidobacterium Longum monograph → Herb & supplement monograph

Lactobacillus Helveticus

Interacts with 182 drugs

Lactobacillus helveticus is a lactic acid bacterium used as a probiotic, often combined with other strains in mood, gut, and general wellness products. Early research is interesting—especial...

Read the full Lactobacillus Helveticus monograph →
Sources

Sources & How We Checked

Jarro-Dophilus EPS 25 Billion CFU's label data comes from the NIH Dietary Supplement Label Database; the ingredient interaction data is from the Natural Medicines database, reviewed by our pharmacists.

Content is written and reviewed by licensed HelloPharmacist pharmacists. See our data sources and editorial standards for how this information is built and checked.

The 88 references behind this product’s interaction data

Every citation that drives the interaction findings for this product’s ingredients, from the evidence-graded Natural Medicines (TRC Healthcare) database. Open an ingredient to browse its citations — links open the study on PubMed or the publisher’s site.

Bifidobacterium Breve 9 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  3. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  4. Ohishi A, Takahashi S, Ito Y, et al. Bifidobacterium septicemia associated with postoperative probiotic therapy in a neonate with omphalocele. J Pediatr. 2010;156(4):679-81. PubMed
  5. Sakurai Y, Watanabe T, Miura Y, et al. Clinical and bacteriologic characteristics of six cases of Bifidobacterium breve bacteremia due to probiotic administration in the neonatal intensive care unit. Pediatr Infect Dis J 2022;41(1):62-65. PubMed
  6. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  7. Wakabayashi Y, Nakayama S, Yamamoto A, et al. First case of necrotizing fasciitis and bacteremia caused by Bifidobacteriumbreve. Anaerobe 2022;76:102613.
  8. Takeda Y, Ota K, Kondo A, et al. A case of necrotizing fasciitis caused by Bifidobacterium breve. IDCases 2022;31:e01667. PubMed
  9. Suwantarat N, Romagnoli M, Wakefield T, Carroll KC. Ventriculoperitoneal shunt infection caused by Bifidobacterium breve. Anaerobe 2014;28:1-3. PubMed

See these in context on the Bifidobacterium Breve monograph →

Lacticaseibacillus Rhamnosus 34 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Saxelin M, Chuang NH, Chassy B, et al. Lactobacilli and bacteremia in southern Finland 1989-1992. Clin Infect Dis 1996;22:564-6. PubMed
  3. Klein G, Zill E, Schindler R, et al. Peritonitis associated with vancomycin-resistant Lactobacillus rhamnosus in a continuous ambulatory peritoneal dialysis patient; organism identification, antibiotic therapy, and case report. J Clin Microbiol 1998;36:
  4. Kalima P, Masterton RG, Roddie PH, et al. Lactobacillus rhamnosus infection in a child following bone marrow transplant. J Infect 1996;32:165-7. PubMed
  5. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 1999;28:1159-60.
  6. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002;109:119-21. PubMed
  7. Kalliomaki M, Salminen S, Arvilommi H et al. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076-1079. PubMed
  8. MacGregor G, Smith AJ, Thakker B, Kinsella J. Yoghurt biotherapy: contraindicated in immunosuppressed patients? Postgrad Med J 2002;78:366-7. PubMed
  9. Land MH, Rouster-Stevens K, Woods CR, et al. Lactobacillus sepsis associated with probiotic therapy. Pediatrics 2005;115:178-81.
  10. De Groote MA, Frank DN, Dowell E, et al. Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome. Pediatr Infect Dis J 2005;24:278-80. PubMed
  11. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM,Prins JM, Koeijers J, Verbon A, Stobberingh E, Geerlings SE. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in p DOI
  12. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
  13. Vahabnezhad E, Mochon AB, Wozniak LJ, Ziring DA. Lactobacillus bacteremia associated with probiotic use in a pediatric patient with ulcerative colitis. J Clin Gastroenterol. 2013;47(5):437-9. PubMed
  14. Wickens KL, Barthow CA, Murphy R, et al. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr. 2017;117(6):804-813.
  15. Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28(12):1491-4. PubMed
  16. Wickens K, Barthow C, Mitchell EA, et al. Maternal supplementation alone with Lactobacillus rhamnosus HN001 during pregnancy and breastfeeding does not reduce infant eczema. Pediatr Allergy Immunol. 2018 May;29(3):296-302.
  17. Husain S, Allotey J, Drymoussi Z, et al. Effects of oral probiotic supplements on vaginal microbiota during pregnancy: a randomised, double-blind, placebo-controlled trial with microbiome analysis. BJOG. 2020;127(2):275-284. PubMed
  18. Sendil S, Shrimanker I, Mansoora Q, Goldman J, Nookala VK. Lactobacillus rhamnosus bacteremia in an immunocompromised renal transplant patient. Cureus. 2020;12(2):e6887. PubMed
  19. Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
  20. Farr A, Sustr V, Kiss H, et al. Oral probiotics to reduce vaginal group B streptococcal colonization in late pregnancy. Sci Rep. 2020;10(1):19745. PubMed
  21. Albarillo FS, Shah U, Joyce C, Slade D. Lactobacillus rhamnosus Infection: A single-center 4-year descriptive analysis. J Glob Infect Dis. 2020;12(3):119-123. PubMed
  22. Pasala S, Singer L, Arshad T, Roach K. Lactobacillus endocarditis in a healthy patient with probiotic use. IDCases. 2020;22:e00915. PubMed
  23. Antoun M, Hattab Y, Akhrass FA, Hamilton LD. Uncommon pathogen, Lactobacillus, causing infective endocarditis: Case report and review. Case Rep Infect Dis. 2020;2020:8833948. PubMed
  24. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
  25. Davidson SJ, Barrett HL, Price SA, Callaway LK, Dekker Nitert M. Probiotics for preventing gestational diabetes. Cochrane Database Syst Rev. 2021;4(4):CD009951. PubMed
  26. Kirjavainen PV, Salminen SJ, Isolauri E. Probiotic bacteria in the management of atopic disease: underscoring the importance of viability. J Pediatr Gastroenterol Nutr. 2003;36(2):223-7. DOI
  27. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  28. Yefet E, Colodner R, Strauss M, Gam Ze Letova Y, Nachum Z. A randomized controlled open label crossover trial to study vaginal colonization of orally administered Lactobacillus reuteri RC-14 and rhamnosus GR-1 in pregnant women at high risk for preterm la
  29. Dani C, Coviello C C, Corsini I I, Arena F, Antonelli A, Rossolini GM. Lactobacillus Sepsis and Probiotic Therapy in Newborns: Two New Cases and Literature Review. AJP Rep. 2016;6(1):e25-9. PubMed
  30. Rubin IMC, Stevnsborg L, Mollerup S, Petersen AM, Pinholt M. Bacteraemia caused by Lactobacillus rhamnosus given as a probiotic in a patient with a central venous catheter: a WGS case report. Infect Prev Pract 2022;4(1):100200. PubMed
  31. Karime C, Barrios MS, Wiest NE, Stancampiano F. Lactobacillus rhamnosus sepsis, endocarditis and septic emboli in a patient with ulcerative colitis taking probiotics. BMJ Case Rep 2022;15(6):e249020.
  32. Ishihara Y, Kanda J, Tanaka K, et al. Severe oral infection due to Lactobacillus rhamnosus during induction chemotherapy for acute myeloid leukemia. Int J Hematol 2014;100(6):607-10. PubMed
  33. Sadowska-Krawczenko I, Paprzycka M, Korbal P, et al. Lactobacillus rhamnosus GG suspected infection in a newborn with intrauterine growth restriction. Benef Microbes. 2014;5(4):397-402. PubMed
  34. Kunz AN, Noel JM, Fairchok MP. Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr. 2004;38(4):457-8.

See these in context on the Lacticaseibacillus Rhamnosus monograph →

Lactiplantibacillus Plantarum 12 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Ducrotté P, Sawant P, Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012;18(30):4012-8.
  3. Krag A, Munkholm P, Israelsen H, von Ryberg B, Andersen KK, Bendtsen F. Profermin is efficacious in patients with active ulcerative colitis--a randomized controlled trial. Inflamm Bowel Dis. 2013;19(12):2584-92. PubMed
  4. Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28(12):1491-4. PubMed
  5. Kumar S, Kumar R, Rohilla L, Jacob N, Yadav J, Sachdeva N. A high potency multi-strain probiotic improves glycemic control in children with new-onset type 1 diabetes mellitus: A randomized, double-blind, and placebo-controlled pilot study. Pediatr Diabete
  6. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  7. Axling U, Önning G, Martinsson Niskanen T, Larsson N, Hansson SR, Hulthén L. The effect of Lactiplantibacillus plantarum 299v together with a low dose of iron on iron status in healthy pregnant women: A randomized clinical trial. Acta Obstet Gynecol Scand
  8. Matsuura H, Kiura Y, Ito T, et al. Lactobacillus bacteremia: a diagnostic clue of rectal cancer. QJM. 2021;114(2):122-123. PubMed
  9. Lazou Ahrén I, Berggren A, Teixeira C, Martinsson Niskanen T, Larsson N. Evaluation of the efficacy of Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2 on aspects of common cold infections in children attending day care: a randomised, doub
  10. Busch R, Gruenwald J, Dudek S. Randomized, double blind and placebo controlled study using a combination of two probiotic lactobacilli to alleviate symptoms and frequency of common cold. Food Nutr Sci 2013;4(11A):13-2. DOI
  11. Bengtsson J, Adlerberth I, Östblom A, Saksena P, Öresland T, Börjesson L. Effect of probiotics (Lactobacillus plantarum 299 plus Bifidobacterium Cure21) in patients with poor ileal pouch function: a randomised controlled trial. Scand J Gastroenterol 2016;
  12. Canaviri-Paz P, Oscarsson E, Kjellström A, Olsson H, Jois C, Håkansson Å. Effects on Microbiota Composition after Consumption of Quinoa Beverage Fermented by a Novel Xylose-Metabolizing L. plantarum Strain. Nutrients 2021;13(10):3318. PubMed

See these in context on the Lactiplantibacillus Plantarum monograph →

Lacticaseibacillus Casei 10 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Orkaby AR, Chen B, Iliaki EF, Sulis CA, Oates DJ. A curious case of Lactobacillus casei in a prosthetic joint: was it the yogurt? J Am Geriatr Soc. 2012;60(6):1177-8.
  3. Shavakhi A, Tabesh E, Yaghoutkar A, Hashemi H, Tabesh F, Khodadoostan M,Minakari M, Shavakhi S, Gholamrezaei A. The effects of multistrain probiotic compound on bismuth-containing quadruple therapy for Helicobacter pylori infection: a randomized placebo-c
  4. Karamali M, Dadkhah F, Sadrkhanlou M, et al. Effects of probiotic supplementation on glycaemic control and lipid profiles in gestational diabetes: a randomized, double-blind, placebo-controlled trial. Diabetes Metab 2016;42(4):234-41. PubMed
  5. Topcuoglu S, Gursoy T, Ovali F, Serce O, Karatekin G. A new risk factor for neonatal vancomycin-resistant Enterococcus colonisation: bacterial probiotics. J Matern Fetal Neonatal Med. 2015;28(12):1491-4. PubMed
  6. Badehnoosh B, Karamali M, Zarrati M, et al. The effects of probiotic supplementation on biomarkers of inflammation, oxidative stress and pregnancy outcomes in gestational diabetes. J Matern Fetal Neonatal Med. 2018 May;31(9):1128-1136.
  7. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed
  8. de Seynes C, Dutronc H, Cremer P, Dupon M. Lactobacillus casei prosthetic joint infection. Med Mal Infect 2018;48(6):422-423. PubMed
  9. Russo A, Angeletti S, Lorino G, et al. A case of Lactobacillus casei bacteraemia associated with aortic dissection: is there a link?. New Microbiol 2010;33(2):175-8.
  10. Rahman A, Alqaisi S, Nath J. A Case of Lactobacillus casei endocarditis associated with probiotic intake in an immunocompromised patient. Cureus. 2023;15(4):e38049. PubMed

See these in context on the Lacticaseibacillus Casei monograph →

Bifidobacterium Longum 21 references
  1. Ha GY, Yang CH, Kim H, Chong Y. Case of sepsis caused by Bifidobacterium longum. J Clin Microbiol 1999;37:1227-8.
  2. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  3. Xiao JZ, Takahashi S, Odamaki T, et al. Antibiotic susceptibility of bifidobacterial strains distributed in the Japanese market. Biosci Biotechnol Biochem. 2010;74(2):336-42. PubMed
  4. Rautava S, Kainonen E, Salminen S, Isolauri E. Maternal probiotic supplementation during pregnancy and breast-feeding reduces the risk of eczema in the infant. J Allergy Clin Immunol. 2012;130(6):1355-60. PubMed
  5. Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S, Scolfaro C. Are probiotics safe? Bifidobacterium bacteremia in a child with severe heart failure. Infez Med. 2019;27(2):175-178.
  6. Pellonperä O, Vahlberg T, Mokkala K, et al. Weight gain and body composition during pregnancy: a randomised pilot trial with probiotics and/or fish oil. Br J Nutr. 2020 Nov 4:1-11. PubMed
  7. Pellonperä O, Mokkala K, Houttu N, et al. Efficacy of fish oil and/or probiotic intervention on the incidence of gestational diabetes mellitus in an at-risk group of overweight and obese women: A randomized, placebo-controlled, double-blind clinical trial PubMed
  8. Shahriari A, Karimi E, Shahriari M, Aslani N, Khooshideh M, Arab A. The effect of probiotic supplementation on the risk of gestational diabetes mellitus among high-risk pregnant women: A parallel double-blind, randomized, placebo-controlled clinical trial PubMed
  9. Esaiassen E, Hjerde E, Cavanagh JP, Simonsen GS, Klingenberg C; Norwegian Study Group on Invasive Bifidobacterial Infections. Bifidobacterium bacteremia: Clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7) PubMed
  10. Enomoto T, Sowa M, Nishimori K, et al. Effects of bifidobacterial supplementation to pregnant women and infants in the prevention of allergy development in infants and on fecal microbiota. Allergol Int 2014;63(4):575-85. PubMed
  11. US Food and Drug Administration (FDA). Dear Healthcare Provider Letter: Warning Regarding Use of Probiotics in Preterm Infants. September 2023. Available at: https://www.fda.gov/media/172606/download?attachment. Accessed November 1, 2023.
  12. Pillai A, Tan J, Paquette V, Panczuk J. Does probiotic bacteremia in premature infants impact clinically relevant outcomes? A case report and updated review of literature. Clin Nutr ESPEN. 2020;39:255-259. PubMed
  13. Sabaté JM, Iglicki F. Effect of Bifidobacterium longum 35624 on disease severity and quality of life in patients with irritable bowel syndrome. World J Gastroenterol 2022;28(7):732-744.
  14. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Dig Dis Sci 2007;52(11) PubMed
  15. Zbinden A, Zbinden R, Berger C, Arlettaz R. Case series of Bifidobacterium longum bacteremia in three preterm infants on probiotic therapy. Neonatology 2015;107(1):56-9.
  16. Tamaki H, Nakase H, Inoue S, et al. Efficacy of probiotic treatment with Bifidobacterium longum 536 for induction of remission in active ulcerative colitis: A randomized, double-blinded, placebo-controlled multicenter trial. Dig Endosc 2016;28(1):67-74.
  17. Bertelli C, Pillonel T, Torregrossa A, et al. Bifidobacterium longum bacteremia in preterm infants receiving probiotics. Clin Infect Dis 2015;60(6):924-7. PubMed
  18. Esaiassen E, Cavanagh P, Hjerde E, Simonsen GS, Støen R, Klingenberg C. Bifidobacterium longum subspecies infantis bacteremia in 3 extremely preterm infants receiving probiotics. Emerg Infect Dis 2016;22(9):1664-6.
  19. Tena D, Losa C, Medina MJ, Sáez-Nieto JA. Peritonitis caused by Bifidobacterium longum: case report and literature review. Anaerobe 2014;27:27-30. PubMed
  20. Sangkanjanavanich S, Pradubpongsa P, Mitthamsiri W, Sangasapaviliya A, Boonpiyathad T. Bifidobacterium infantis 35624 efficacy in patients with uncontrolled asthma: A randomized placebo-controlled trial. Ann Allergy Asthma Immunol 2022;129(6):790-792. PubMed
  21. Wilson HL, Ong CW. Bifidobacterium longum vertebrodiscitis in a patient with cirrhosis and prostate cancer. Anaerobe 2017;47:47-50. PubMed

See these in context on the Bifidobacterium Longum monograph →

Lactobacillus Helveticus 2 references
  1. Pierce A. The American Pharmaceutical Association Practical Guide to Natural Medicines. New York: The Stonesong Press, 1999:19.
  2. Rossi F, Amadoro C, Gasperi M, Colavita G. Lactobacilli infection case reports in the last three years and safety implications. Nutrients. 2022;14(6):1178. PubMed

See these in context on the Lactobacillus Helveticus monograph →

Parts of this content are provided by the Therapeutic Research Center, LLC.

DISCLAIMER: Currently this does not check for drug-drug interactions. This is not an all-inclusive comprehensive list of potential interactions and is for informational purposes only. Not all interactions are known or well-reported in the scientific literature, and new interactions are continually being reported. Input is needed from a qualified healthcare provider including a pharmacist before starting any therapy. Application of clinical judgment is necessary.

© 2021 Therapeutic Research Center, LLC

Keep exploring
Supplement interaction checker › Check any supplement or product against your medications Drug–drug interactions › Check two or more of your medications against each other Browse medications A–Z › Every drug we've checked against herbs & supplements NDC & pricing lookup › Find a drug’s NDCs, packaging and costs Ask a pharmacist › Free, personal answer from our licensed team